Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout (Q34400603)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout |
scientific article |
Statements
1 reference
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout (English)
1 reference
Michael A Becker
1 reference
H Ralph Schumacher
1 reference
Robert L Wortmann
1 reference
Patricia A MacDonald
1 reference
William A Palo
1 reference
Denise Eustace
1 reference
Laurent Vernillet
1 reference
Nancy Joseph-Ridge
1 reference
1 March 2005
1 reference
1 reference
52
1 reference
3
1 reference
916-923
1 reference
Identifiers
1 reference
1 reference